Last reviewed · How we verify
Polyclonal IgG
At a glance
| Generic name | Polyclonal IgG |
|---|---|
| Also known as | Immunoglobulins |
| Sponsor | Federico II University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bortezomib in Rejection of Kidney Transplants (PHASE2)
- Pulpotomy Medications in Primary Teeth (NA)
- Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19 (PHASE2, PHASE3)
- First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients (PHASE1, PHASE2)
- Cardiac Safe Transplants for Systemic Sclerosis (PHASE2, PHASE3)
- Autologous Transplant To End NMO Spectrum Disorder (PHASE2, PHASE3)
- Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection (PHASE2)
- Human IgGs and Endothelial Function in Vivo in Humans (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyclonal IgG CI brief — competitive landscape report
- Polyclonal IgG updates RSS · CI watch RSS
- Federico II University portfolio CI